Understanding the US Supreme Court Decision: Association for Molecular Pathology v. Myriad Genetics
Presented by:
Eric E. Williams, Pharm.D.
Thursday, July 25, at 2:00 pm to 3:30 pm
Veterinary and Biomedical Research Building
The Science Forum-Room 305
Also Video Streaming available at WSU/Spokane in Room SAC 515.
On June 13, 2013, the Supreme Court issued a highly anticipated decision in the biotechnology field: Associated for Molecular Pathology v. Myriad Genetics. The Court’s unanimous decision found that a naturally occurring DNA segment is a product of nature and is not patent eligible merely because it has been “isolated.” However, the Court determined that cDNA is patent eligible because it is not naturally occurring. This presentation explores the reasoning behind the Court’s decision and its impact on the science behind patenting DNA-centric inventions.